Lidocaine Pharmacokinetics During Tumescent Infiltrative Anaesthesia for Mastectomy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01687348|
Recruitment Status : Completed
First Posted : September 18, 2012
Last Update Posted : January 25, 2016
Prospective, monocentric, open-label study conducted in women requiring mastectomy and eligible for tumescent infiltrative anaesthesia.
Blood samples will be collected during 48h after start of infiltration. Total and free lidocaine concentrations measurements will be determined by gas chromatography. Visual analogic scale scores to evaluate postoperative pain and all data concerning analgesic drugs and adverse effects will be collected.
Population pharmacokinetic parameters will be estimated using NONMEM software and covariates influence on parameters variability will be tested.
Primary outcome value: Population pharmacokinetic parameters with possible covariates influence on variability.
Patients and period of study: n=30 patients enrolled during 24 months, total study duration: 30 months.
|Condition or disease||Intervention/treatment||Phase|
|Mastectomy||Drug: lidocaine aguettant||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Lidocaine Pharmacokinetics During Tumescent Infiltrative Anaesthesia for Mastectomy.|
|Study Start Date :||November 2012|
|Actual Primary Completion Date :||November 2015|
|Actual Study Completion Date :||December 2015|
Drug: lidocaine aguettant
- Peak Plasma Concentration (Cmax) of 'drug lidocaine'" [ Time Frame: 36 MONTHS ]during tumescent infiltrative anaesthesia for mastectomy.
- analgesic postoperative efficacy [ Time Frame: 36 MONTHS ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01687348
|Assistance Publique Hopitaux de Marseille|
|Marseille, France, 13354|
|Study Director:||BERNARD BELAIGUES||Assistance Publique hôpitaux de Marseille|